Carbapenemase-producing Enterobacterales (CPE) represent an increasing global problem. Since 2016, the carbapenemase oxacillinase (OXA)-244, a single amino-acid variant of OXA-48 and present in
Escherichia coli ST38, has been recognized as an emerging carbapenemase variant in several European countries. This prompted the ECDC to publish a rapid risk assessment in February 2021 with a follow-up in July.
1 The increase of OXA-244 was also observed in the Netherlands after analysis of the data from the Dutch national CPE surveillance. For the Dutch CPE surveillance, medical microbiology laboratories are requested to send isolates suspected of carbapenemase production, with a meropenem MIC of ≥0.25 mg/L and/or an imipenem MIC of ≥1 mg/L, or evidence of carbapenemase production, to the National Institute for Public Health and the Environment. Illumina next-generation sequencing (NGS) was performed on all isolates testing positive for carbapenemase production, from persons with a personal identifier code present to be able to detect multiple isolates from the same person.
2 Between January 2016 and June 2021, from 1203 unique CPE isolates (unique combination of species and carbapenemase gene per person), NGS results were available. Of these, 394 (33%; 394/1203) isolates were
E. coli and NGS data were used for Clermont phylotyping,
3 classical MLST, whole-genome (wg)MLST analysis using an in-house
E. coli wgMLST scheme, and core SNP analysis [Figure 1 and Figure S1(a and b), available as Supplementary data at
JAC Online] .
4 Among the 394 sequenced carbapenemase-producing
E. coli isolates, 85 were MLST ST38, of which 30 contained
blaOXA-244. Seventeen of these 30 OXA-244-producing ST38
E. coli isolates formed a genetic cluster based on wgMLST and was termed EcoCluster-023. A genetic wgMLST cluster is defined as ≥2 isolates that differ by ≤25 wgMLST alleles.
4 The 17 EcoCluster-023 isolates differed by 1 to 21 wgMLST alleles from each other [Figure 1(b)]. In addition, core SNP analysis revealed 1 to 62 SNP differences among the 17 EcoCluster-023 isolates. [Figure S1(a and b) ]. The wgMLST allelic variation and SNP differences may be explained since isolates were from cultures taken between August 2016 and May 2021, with 13 (76%) isolates from 2020 and 2021. The 17 isolates were derived from 17 different patients, and were submitted by 13 different laboratories from eight different provinces. The median age of the patients was 54 years (range 8 to 92) and 10 (59%) patients were women. Nine (53%) isolates were cultured from urine, and the other eight from rectal swabs. This percentage of isolates derived from urine cultures was considerably higher than the 80 (21.2%) among the other 377 carbapenemase-producing
E. coli isolates from this study excluding this cluster. All EcoCluster-023 isolates produced carbapenemase, as tested with the carbapenem inactivation method.
5 The MIC of meropenem was below 1.5 mg/L for all isolates, as determined by Etest, therefore all isolates were susceptible according to EUCAST [Figure 1(c)]. Information on risk factors was available for 16 patients. There was no evidence for direct patient-to-patient transmission in this group. Eight (50%) persons had a known connection with Middle Eastern countries, Turkey in five patients and Syria in three. This was either as recent hospitalization in the previous 2 months (
n = 2) or up to a year ago (
n = 3), or as country of birth (
n = 6, including three with previous hospitalization there). Recent hospitalization abroad up to 2 months previous, is considered a risk factor in Dutch national guidelines. The prevalence of OXA-244 in Middle Eastern countries is unknown.